Abrad

Symptomatic treatment of chronic stable angina pectoris in CAD patients w/ normal sinus rhythm & heart rate ≥70 bpm in adults unable to tolerate or w/ CI to β-blockers; or in combination w/ β-blockers in patients inadequately controlled w/ an optimal β-blocker dose. Chronic heart failure NYHA II-IV w/ systolic dysfunction in patients in sinus rhythm & whose heart rate is ≥75 bpm; in combination w/ standard therapy including β-blocker or when β-blocker is contraindicated or not tolerated.

Symptomatic treatment of chronic stable angina pectoris Patient <75 yr Max starting dose: 5 mg bd. Max maintenance dose: 7.5 mg bd. Chronic heart failure Initially 5 mg bd, may increase to 7.5 mg bd after 2 wk if resting heart rate is persistently >60 bpm or may decrease to 2.5 mg bd if resting heart rate is persistently <50 bpm or in case of symptoms related to bradycardia. Elderly ≥75 yr Consider lower starting dose of 2.5 mg bd before up-titration if necessary.

Should be taken with food.

Hypersensitivity. Resting heart rate <70 bpm prior to treatment. Cardiogenic shock. Acute MI. Severe hypotension (<90/50 mmHg). Sick sinus syndrome. SA block. Unstable or acute heart failure. Pacemaker dependent. Unstable angina. 3rd degree AV block. Combination w/ strong CYP450 3A4 inhibitors (eg, azole antifungals, macrolides, HIV PIs & nefazodone); moderate CYP3A4 inhibitors w/ heart rate reducing properties (eg, verapamil or diltiazem). Severe hepatic insufficiency. Women of childbearing potential not using appropriate contraceptive measures. Pregnancy & lactation.

Anti-Anginal Drugs

C01EB17 - ivabradine ; Belongs to the class of other cardiac preparations.

POM